CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors. (25th May 2019)
- Record Type:
- Journal Article
- Title:
- CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors. (25th May 2019)
- Main Title:
- CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors
- Authors:
- Miki, Masami
Oono, Takamasa
Fujimori, Nao
Takaoka, Takehiro
Kawabe, Ken
Miyasaka, Yoshihiro
Ohtsuka, Takao
Saito, Daisuke
Nakamura, Masafumi
Ohkawa, Yasuyuki
Oda, Yoshinao
Suyama, Mikita
Ito, Tetsuhide
Ogawa, Yoshihiro - Abstract:
- Abstract: Although the postoperative recurrence rate for pancreatic neuroendocrine tumors (PNETs) is reported to be 13.5%‐30%, the paucity of valuable biomarkers to predict recurrence poses a problem for the early detection of relapse. Hence, this study aimed to identify new biomarkers to predict the recurrence of PNETs. We performed RNA sequencing (RNA‐Seq) on RNA isolated from frozen primary tumors sampled from all localized G1/G2 PNETs resected curatively from 1998 to 2015 in our institution. We calculated differentially expressed genes (DEGs) in tumor with and without recurrence (≥3 years) for the propensity‐matched cohort. Gene ontology analysis for the identified DEGs was also performed. Furthermore, we evaluated the expression levels of candidate genes as recurrence predictors via immunostaining. Comparison of transcriptional levels in tumors with and without recurrence identified 166 DEGs. Up‐ and downregulated genes with high significance in these tumors were mainly related to extracellular organization and cell adhesion, respectively. We observed the top three upregulated genes, C‐type lectin domain family 3 member A (CLEC3A), matrix metalloproteinase‐7 (MMP7), and lipocalin2 (LCN2) immunohistochemically and compared their levels in recurrent and nonrecurrent tumors. Significantly higher recurrence rate was shown in patients with positive expression of CLEC3A ( P = 0.028), MMP7 ( P = 0.003), and LCN2 ( P = 0.040) than that with negative expression. We identifiedAbstract: Although the postoperative recurrence rate for pancreatic neuroendocrine tumors (PNETs) is reported to be 13.5%‐30%, the paucity of valuable biomarkers to predict recurrence poses a problem for the early detection of relapse. Hence, this study aimed to identify new biomarkers to predict the recurrence of PNETs. We performed RNA sequencing (RNA‐Seq) on RNA isolated from frozen primary tumors sampled from all localized G1/G2 PNETs resected curatively from 1998 to 2015 in our institution. We calculated differentially expressed genes (DEGs) in tumor with and without recurrence (≥3 years) for the propensity‐matched cohort. Gene ontology analysis for the identified DEGs was also performed. Furthermore, we evaluated the expression levels of candidate genes as recurrence predictors via immunostaining. Comparison of transcriptional levels in tumors with and without recurrence identified 166 DEGs. Up‐ and downregulated genes with high significance in these tumors were mainly related to extracellular organization and cell adhesion, respectively. We observed the top three upregulated genes, C‐type lectin domain family 3 member A (CLEC3A), matrix metalloproteinase‐7 (MMP7), and lipocalin2 (LCN2) immunohistochemically and compared their levels in recurrent and nonrecurrent tumors. Significantly higher recurrence rate was shown in patients with positive expression of CLEC3A ( P = 0.028), MMP7 ( P = 0.003), and LCN2 ( P = 0.040) than that with negative expression. We identified CLEC3A, MMP7, and LCN2 known to be associated with the phosphatidylinositol‐3‐kinase/Akt pathway, as potential novel markers to predict the postoperative recurrence of PNETs. Abstract : Three proteins, CLEC3A, MMP7, and LCN2 were identified as novel predictors for recurrence by RNA‐sequencing analysis. Additionally, we demonstrated that the recurrence potential in pancreatic neuroendocrine tumors is characterized by the upregulation of genes related to ECM organization and cell adhesion for the first time. … (more)
- Is Part Of:
- Cancer medicine. Volume 8:Number 8(2019:Jul.)
- Journal:
- Cancer medicine
- Issue:
- Volume 8:Number 8(2019:Jul.)
- Issue Display:
- Volume 8, Issue 8 (2019)
- Year:
- 2019
- Volume:
- 8
- Issue:
- 8
- Issue Sort Value:
- 2019-0008-0008-0000
- Page Start:
- 3748
- Page End:
- 3760
- Publication Date:
- 2019-05-25
- Subjects:
- C type lectin domain family 3 member A -- lipocalin2 -- matrix metalloproteinase‐7 -- pancreatic neuroendocrine tumors
616.994005 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2045-7634 ↗ - DOI:
- 10.1002/cam4.2232 ↗
- Languages:
- English
- ISSNs:
- 2045-7634
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11180.xml